Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188520 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
A Phase 1 study of ER+ HER2- Advanced Breast Cancer and High-grade Serous Ovarian Cancer (HGSOC), sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 564
- Enrollment target
- 14
- Study locations
NCT06188520 is a Phase 1 study of ER+ HER2- Advanced Breast Cancer and High-grade Serous Ovarian Cancer (HGSOC) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 564 participants. The trial reports 14 study locations across 5 states.
The verdict
NCT06188520, a Phase 1 study of ER+ HER2- Advanced Breast Cancer and High-grade Serous Ovarian Cancer (HGSOC), is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 564 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
Conditions Studied
Interventions
- DRUG Camizestrant
- DRUG Palbociclib
- DRUG Abemaciclib
- DRUG Ribociclib
- DRUG AZD8421
Study Locations (14)
Other
- Research Site - East Melbourne
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Pamplona
- Research Site - Valencia
- Research Site - Cambridge
- Research Site - Leeds
- Research Site - London
- Research Site - Manchester
Missouri
- Research Site - St Louis
Rhode Island
- Research Site - Providence
Tennessee
- Research Site - Nashville
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2027-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06188520
The ClinicalTrials.gov registry entry for NCT06188520 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 564 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with ER+ HER2- Advanced Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Camizestrant is the first listed.
NCT06188520 reports 14 study locations spanning 5 distinct geographic areas - top geographies include Other, Missouri, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06188520 about?
NCT06188520 is a clinical study titled "A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors". This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
What is the current status of trial NCT06188520?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 564 participants. The study started on 2023-12-05. Estimated completion is 2027-08-04.
What conditions does trial NCT06188520 study?
This clinical trial studies the following conditions: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC).
What interventions are being tested in trial NCT06188520?
The interventions under investigation include: Camizestrant (DRUG), Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG), AZD8421 (DRUG).
Who is sponsoring clinical trial NCT06188520?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06188520 being conducted?
This trial has 14 study locations across Missouri, Rhode Island, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ER+ HER2- Advanced Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
ER+ HER2- Advanced Breast Cancer
All registered trials for this condition
High-grade Serous Ovarian Cancer (HGSOC)
All registered trials for this condition
Missouri
All trials with a study site in Missouri
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.